| Depression |
1 |
0.72 |
| Psychopharmacology |
0 |
0.41 |
| Addiction |
0 |
0.36 |
| Drug Abuse |
0 |
0.34 |
| Abuse |
0 |
0.32 |
| Brain |
0 |
0.32 |
| Face |
0 |
0.32 |
| Receptors |
0 |
0.32 |
| Brain Stimulation |
0 |
0.29 |
| Substance Abuse |
0 |
0.29 |
| Antidepressant drug |
0 |
0.24 |
| Major Depression |
0 |
0.24 |
| Residency |
0 |
0.24 |
| Somatic |
0 |
0.24 |
| Opioids |
0 |
0.22 |
| Medical Life |
0 |
0.21 |
| Investment |
0 |
0.16 |
| Jobs |
0 |
0.16 |
| Psychotherapy |
0 |
0.16 |
| Anxiolytic |
0 |
0.08 |
| Biomarker |
0 |
0.08 |
| Diagnostic and Statistical Manual of Mental Disorders |
0 |
0.08 |
| Drug Development |
0 |
0.08 |
| Financial Reimbursement |
0 |
0.08 |
| Functional MRI |
0 |
0.08 |
| Hand |
0 |
0.08 |
| Medical Literature |
0 |
0.08 |
| Mental Illness |
0 |
0.08 |
| Mood Disorders |
0 |
0.08 |
| Preventive Screening |
0 |
0.08 |
| Proteomics |
0 |
0.08 |
| Psychosocial |
0 |
0.08 |
| Repetitive Transcranial Magnetic Stimulation |
0 |
0.08 |
| Weakness |
0 |
0.08 |
| Anxiety Disorder |
0 |
0.05 |
| Genomic Medicine |
0 |
0.05 |
| Revenue and Practice Management |
0 |
0.05 |
| Schizophrenia |
0 |
0.05 |